Figure 1

Anti-DNAM-1 monoclonal antibody does not protect from the development of collagen-induced arthritis at clinical assessment. (a) Clinical evidence of arthritis with redness and swelling of the paws involving tarsus, ankle and toes in the three groups: the first group was treated with anti-DNAM-1 monoclonal antibody (n = 7); the second was treated with control IgG antibody (n = 7) and the third with PBS (n = 7). Pictures were taken at day 30. (b) Clinical score similarly increased in the three groups from the injection to the end point. This score had a trend to be lower in the group injected with anti-DNAM-1 without significance. The blue curve represents the scores obtained in mice treated with AC anti-DNAM1 (n = 7), the red one those obtained in mice receiving control IgG (n = 7) and the green one the scores in mice treated with PBS (n = 7). (c and d) Median of the mean clinical score and of the maximal score were not significantly different between mice injected with anti-DNAM-1 and those treated with control IgG and PBS, but there was a trend for lower score in mice injected with anti-DNAM-1. Values are the median ± IQR.